Tampa, United States
Aster Insights is a pioneering company in the healthcare and information technology industries, aiming to revolutionize oncology medical product discovery and development through scientific and clinical intelligence. Founded in 2006, the company's mission is rooted in the belief that personalized medicine commences with a comprehensive understanding of an individual's lifetime. They have built their foundation on trust and long-term patient connections, in conjunction with strong alliances in academia and the life sciences sector, to drive essential progress in curing cancer.
Aster Insights leads the Oncology Research Information Exchange Network (ORIEN®), bringing together top academic cancer centers to conduct Total Cancer Care® (TCC®), the world's most extensive ongoing observational research study in oncology. This initiative serves as the basis for groundbreaking insights and advancements in oncology.
The company has excelled in accelerating the life cycle of oncology medical product development and has expertise in scientific and clinical intelligence. Their unique partnership with patients, academia, and industry provides them with the ability to empower their partners in discovering new targets and biomarkers, enhancing cancer detection, understanding new treatments, finding new indications, and expediting clinical trials.
The latest milestone for Aster Insights was a Private Equity Round investment on 17 March 2021, with investments from Clayton Dubilier & Rice, McKesson Ventures, and Merck Global Health Innovation Fund. This infusion of capital signifies a strong vote of confidence from prominent investors in the company’s vision and capabilities. As Aster Insights continues to reshape the landscape of cancer research, treatment, and prevention, their dedication to innovation and impact is poised to make significant contributions to the field of oncology.
